

| OMB APPROVAL                                 |           |
|--|-----------|
| OMB Number:                                  | 3235-0287 |
| Estimated average burden hours per response: | 0.5       |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

|   |   |   |
|---|---|---|
| 1. Name and Address of Reporting Person*<br><u>MCENANY PATRICK J</u><br><br>(Last) (First) (Middle)<br>355 ALHAMBRA CIRCLE, SUITE 801<br><br>(Street)<br>CORAL FL 33134<br>GABLES<br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>CATALYST PHARMACEUTICALS, INC. [ CPRX ]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)<br><input checked="" type="checkbox"/> Director 10% Owner<br><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)<br><b>President and CEO</b> |
|   | 3. Date of Earliest Transaction (Month/Day/Year)<br>11/18/2022                                |   |
| 4. If Amendment, Date of Original Filed (Month/Day/Year)  |   |   |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3)           | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |                         | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Beneficial Ownership (Instr. 4) |
|---|--------------------------------------|--|--------------------------------|---|---|------------|-------------------------|---|--|--|
|   |                                      |  | Code                           | V | Amount  | (A) or (D) | Price                   |   |  |  |
| Common stock, par value \$0.001 per share | 11/18/2022                           |  | M                              |   | 350,000   | A          | \$2.24                  | 4,252,606   | D  |  |
| Common stock, par value \$0.001 per share | 11/18/2022                           |  | S                              |   | 350,000 <sup>(1)</sup>  | D          | \$15.622 <sup>(2)</sup> | 3,902,606   | D  |  |
| Common stock, par value \$0.001 per share | 11/21/2022                           |  | M                              |   | 150,000   | A          | \$2.24                  | 4,052,606   | D  |  |
| Common stock, par value \$0.001 per share | 11/21/2022                           |  | S                              |   | 150,000 <sup>(1)</sup>  | D          | \$15.332 <sup>(3)</sup> | 3,902,606   | D  |  |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |         | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |       |
|--|--|--------------------------------------|--|--------------------------------|---|--|---------|--|-----------------|---|--|--|---|--|-------|
|  |  |                                      |  | Code                           | V | (A)  | (D)     | Date Exercisable   | Expiration Date |   |  |  |   |  | Title |
| Options to purchase common stock           | \$2.24   | 11/18/2022                           |  | M                              |   |  | 350,000 | (4)  | 12/19/2025      | Common Stock  | 350,000                                    | \$0  | 3,015,834   | D  |       |
| Options to purchase common stock           | \$2.24   | 11/21/2022                           |  | M                              |   |  | 150,000 | (4)  | 12/19/2025      | Common Stock  | 150,000                                    | \$0  | 2,865,834   | D  |       |

Explanation of Responses:

- Shares were sold for personal reasons. Shares were not sold as a result of any disagreement with the Company and Mr. McEnany remains a director and an officer of the Company.
- Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from \$15.50 to \$16.06 per share.
- Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from \$15.19 to \$15.55 per share.
- Options vested in three equal tranches on December 19, 2019, 2020 and 2021.

/s/ Patrick J. McEnany 11/22/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.